Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.

About Regeneron. Our mission is to use the power of science to bring new medicines to patients ... over and over again. We are a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.

Learn how Regeneron is actively working on testing existing medicines and developing new antibodies to combat the COVID-19 pandemic.

2025年2月26日 · FDA decision expected by July 30, 2025. TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R) follicular …

The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts.

In 2023, we invested $4.4 billion into R&D, supporting research in areas including allergic and inflammatory diseases, cardiovascular and metabolic diseases, neuroscience, oncology and hematology, ophthalmology, rare diseases and other therapeutic areas.

2025年2月4日 · Regeneron Corporate Presentation F E B R U A R Y 2 0 2 5 This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially.

2024年12月19日 · Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings Evaluated against current standards of care, single doses of REGN7508 and

We are a team of original thinkers who work together to create life-transforming medicines for people with serious diseases. Whether it's in the laboratory or at lunch, our company is built on breakthrough ideas, diverse personal strengths and a culture of connection.

Tarrytown, New York, United States of America / Dublin, Ireland / Uxbridge, Middlesex, United Kingdom / Basking Ridge, New Jersey, United States of America